Early improvements in signs and symptoms predict clinical response to baricitinib in patients with moderate-to-severe atopic dermatitis
Clinical and Experimental Dermatology · 2023
DOI: 10.1093/ced/llad129 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Dermatology, 2023. Verfasst von Thomas Bieber und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Allergy, University of Bonn, Bonn, Germany. Hauptthemen laut MEDLINE: Dermatitis, Atopic. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Eli Lilly and Company.
Abstract (Originalsprache)
Background
Early prediction of therapeutic response can optimize treatment strategies in atopic dermatitis (AD). Baricitinib is approved for moderate-to-severe AD in Europe, Japan and other countries.
Objectives
To identify early clinical improvements that can reliably predict a later clinical response to baricitinib in adults with moderate-to-severe AD.
Methods
Using data from one topical corticosteroid combination study [BREEZE-AD7 (NCT03733301)] and data pooled from two monotherapy studies [(BREEZE-AD1 (NCT03334396) and BREEZE-AD2 (NCT03334422)], we calculated the sensitivity and specificity, along with the positive predictive value (PPV) and negative predictive value (NPV), of predefined changes in single and combined clinical scores at weeks 2, 4 and 8, to predict clinical response at week 16. Clinical response was defined as ≥ 75% improvement in Eczema Area and Severity Index (EASI 75), ≥ 4-point improvement in Itch Numeric Rating Scale (Itch NRS ≥ 4), or a combination of both.
Results
Composite predictors had higher predictive accuracy for week 16 response outcomes than did single parameters. This was evident as early as week 4 for the combination of EASI 50 or Itch NRS ≥ 3 and of validated Investigator Global Assessment for AD (vIGA-AD) score ≤ 2 or Itch NRS ≥ 3 (sensitivity 87–100%; NPV 68–100%). The predictive accuracy of these composite clinical predictors for week 16 response outcomes was highest at week 8 (sensitivity 92–100%; NPV 80–100%). At both weeks 4 and 8, EASI 50 or Itch NRS ≥ 3 had higher sensitivity and NPV than did vIGA-AD score ≤ 2 or Itch NRS ≥ 3.
Conclusions
Improvement in signs and symptoms early during treatment with baricitinib 4 mg once daily predicts clinical response at week 16, providing a tool for dermatologists when choosing treatment strategies for patients with moderate-to-severe AD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology and Allergy, University of Bonn, Bonn, Germany.
- University Hospital, Bonn, Germany.
- Christine Kühne - Center for Allergy Research and Education, Davos, Switzerland.
- Department of Dermatology, Bispebjerg Hospital, Copenhagen, Denmark.
- Clinical Medicine, Trinity College Dublin, Dublin, Ireland.
- Department of Dermatology, Saitama Medical University, Saitama, Japan.
ORCID-Profile: Thomas Bieber, Jacob P Thyssen, Alan D Irvine, Yuichiro Tsunemi, Michael J Cork
Förderung
- Eli Lilly and Company
Zitieren
APA
Bieber, T., Thyssen, J. P., Irvine, A. D., Tsunemi, Y., Chen, Y. F., Sun, L., Schloebe, A., Riedl, E., & Cork, M. J. (2023). Early improvements in signs and symptoms predict clinical response to baricitinib in patients with moderate-to-severe atopic dermatitis. Clinical and Experimental Dermatology. https://doi.org/10.1093/ced/llad129
Vancouver
Bieber T, Thyssen JP, Irvine AD, Tsunemi Y, Chen YF, Sun L, et al. Early improvements in signs and symptoms predict clinical response to baricitinib in patients with moderate-to-severe atopic dermatitis. Clinical and Experimental Dermatology. 2023. doi:10.1093/ced/llad129
BibTeX
@article{Bieber2023,
author = {Bieber, Thomas and Thyssen, Jacob P and Irvine, Alan D and Tsunemi, Yuichiro and Chen, Yun-Fei and Sun, Luna and Schloebe, Andrea and Riedl, Elisabeth and Cork, Michael J},
title = {Early improvements in signs and symptoms predict clinical response to baricitinib in patients with moderate-to-severe atopic dermatitis},
journal = {Clinical and Experimental Dermatology},
year = {2023},
doi = {10.1093/ced/llad129}
}
EUVIMED